Zhijie Ding is the manager of real world value & evidence, immunology for The Janssen Pharmaceutical Companies of Johnson & Johnson. In this role he demonstrates the value of STELARA® in Crohn’s disease by generating and communicating high quality real-world evidence through collaboration with internal and external stakeholders. Ding contributes to the U.S. market access scientific strategy for STELARA® by providing insights from real-world evidence and health economics studies. Additionally, he supports the launch of STELARA® in a new indication (ulcerative colitis) by collaborating with cross-functional teams at Janssen Pharmaceuticals.
Read more HPM alumni news...
2/06/2020